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Abstract We characterized truncations of the human vasopres-
sin V2 receptor to determine the role of the intracellular C-
terminus (comprising about 44 amino acids) in receptor function
and cell surface expression. In contrast to the wild-type receptor,
the naturally occurring mutant R337X failed to confer specific
[3H]AVP binding to transfected cells. In addition, no vasopres-
sin-sensitive adenylyl cyclase was detectable in membrane
preparations of these cells. Laser scanning microscopy revealed
that c-myc epitope- or green fluorescent protein-tagged R337X
mutant receptors were retained within the endoplasmic reticulum.
Increasing the number of C-terminal residues (truncations after
codons 348, 354 and 356) restored G protein coupling, but
revealed a length-dependent reduction of cell surface expression.
Replacement of positively charged residues within the C-terminus
by glutamine residues also decreased cell surface expression. A
chimeric V2 receptor with the C-terminus replaced by that of the
L2-adrenergic receptor did not bind [3H]AVP and was retained
within the cell. These data suggest that residues in the N-terminal
part of the C-terminus are necessary for correct folding and that
C-terminal residues are important for efficient cell surface
expression.
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1. Introduction
The vasopressin V2 receptor (V2 receptor) belongs to the
large family of G protein-coupled receptors (GPCRs), struc-
turally de¢ned by seven transmembrane domains, an extra-
cellular N- and an intracellular C-terminus. The lengths of
the intracellular C-termini are highly variable throughout
the protein family. In a comparative analysis of 204 di¡erent
GPCRs it was found that the C-termini carry minimally 12
and maximally 162 amino acids [1]. Only the GnRH receptor,
not considered in this study, completely lacks an intracellular
C-terminus.
It was shown that the C-terminus of bovine rhodopsin is
important for correct folding: a mutant with six residues after
the seventh transmembrane domain was functional, whereas a
mutant with only one residue was unable to bind retinal. The
length of the C-terminus appeared to be more critical than the
presence of speci¢c residues [2]. In the V2 receptor a naturally
occurring mutant with only nine amino acids after the seventh
transmembrane domain (R337X), found in patients with X-
linked nephrogenic diabetes insipidus [3], was demonstrated to
be only core-glycosylated and thus likely to be retained within
the endoplasmic reticulum (ER) [4].
We expressed the mutant R337X transiently or stably and
investigated functional properties (ligand binding, activation
of adenylyl cyclase) of intact cells and membrane preparations
and analyzed the cellular localization of the mutant in ¢xed
and living cells. In addition, the role of the length of the
intracellular C-terminus and of basic residues for e⁄cient
cell surface expression was examined.
2. Materials and methods
2.1. Radiochemicals
[3H]AVP (64.8 Ci/mmol), and [K-32P]ATP (V30 Ci/mmol) were
from NEN (Boston, MA, USA).
2.2. Cell culture
Madin-Darby canine kidney (MDCK), COS.M6 and human em-
bryonic kidney (HEK) cells were cultured in DMEM and Chinese
hamster ovary (CHO) cells in F12 medium containing 10% heat-in-
activated fetal calf serum, penicillin (100 units/ml) and streptomycin
(100 Wg/ml), and in case of stably transfected cell clones G418 (400 Wg/
ml).
2.3. Transient and stable expression of V2 receptors
For transient transfection, COS.M6 or HEK cells were plated at a
density of 500 000 cells/60 mm dish, washed once with serum-free
DMEM and incubated with a mixture of 30 Wl SuperFect (Qiagen,
Hilden, Germany) and 5 Wg of plasmid DNA in 1.1 ml serum-free
DMEM. After 2 h the mixture was replaced by complete medium. For
binding experiments with intact cells, cells were passaged the follow-
ing day onto 24 well plates (4^5U105 cells/well) and investigated 2 or
3 days after transfection. For experiments with membranes, cells were
kept on the dishes and grown for 2 or 3 days after transfection. Stable
transfection of MDCK or CHO cells was performed as described [5].
2.4. Receptor constructs
Site-directed mutagenesis of the V2 receptor cDNA was performed
as described recently [5]. Oligonucleotide sequences are available upon
request. For the construction of the V2 receptor/L2-adrenergic recep-
tor chimera the region encoding amino acids 327^413 of the L2-adre-
nergic receptor was ampli¢ed by PCR, using plasmid pBC-L2 as tem-
plate (kindly provided by Martin Lohse, Wuºrzburg, Germany).
Oligonucleotides used for the ampli¢cation introduced restriction sites
for NsiI at the 5P end and for XbaI at the 3P end after the termination
codon. The plasmid pRCDN2 [5] carrying the V2 receptor cDNA and
the PCR product were cut with NsiI and XbaI, and the cut PCR
product was cloned in frame into the NsiI/XbaI cut plasmid. For
the construction of fusions consisting of the wild-type V2 receptor
and the auto£uorescent red-shifted variant of the green £uorescent
protein (EGFP), the V2 receptor cDNA was cut from the plasmid
pEU367.PhoA [6] with SacI and BamHI and cloned into the SacI/
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BamHI cut vector pEGFP-N1 (Clontech, Heidelberg, Germany). The
resulting fusion protein consisted of the V2 receptor, lacking the C-
terminal four amino acids, and the EGFP (pV2R.EGFP). For con-
struction of the fusion consisting of the R337X mutant and the EGFP
we used PCR. The V2 receptor cDNA fragment was ampli¢ed with a
5P oligonucleotide (corresponding to nucleotides 412^429 of the V2
receptor cDNA) and a 3P oligonucleotide introducing a restriction site
for BamHI after codon 336 of the V2 receptor. The PCR product was
then cut with PmlI/BamHI and cloned in frame into the PmlI/BamHI
cut pV2R.EGFP plasmid, resulting in plasmid pL336.EGFP. All
clones were veri¢ed by sequencing. The construction of N-terminally
c-myc epitope-tagged receptors (insertion of the decapeptide EQKLI-
SEEDL after methionine 3) and their functional characterization is
described elsewhere (Andersen-Beckh, B., Dehe, M., Muºller, H., Lie-
benho¡, U., Schuºlein, R., Oksche, A. and Rosenthal, W., in prepara-
tion). The c-myc epitope did not alter the functional properties of the
V2 receptor (a⁄nity for [3H]AVP, EC50 of AVP for stimulation of
adenylyl cyclase).
2.5. [3H]AVP binding
Binding of [3H]AVP to intact cells was performed as described
recently [5] but using 24 well plates. The procedure for transfection
and plating of the cells is described above. For membrane binding,
cells were washed in PBS (137 mM NaCl, 2.7 mM KCl, 1.5 mM
KH2PO4, 8.0 mM Na2HPO4, pH 7.4), harvested with a rubber police-
man and centrifuged at 400Ug for 10 min. The pellet was resuspended
in Tris-BAME bu¡er (50 mM Tris, 0.15 mM bacitracin, 0.0015%
aprotinin, 10 mM MgCl2, 2 mM EGTA, pH 7.3), homogenized
with a glass/te£on homogenizer (10 strokes), and centrifuged at
26 000Ug for 30 min. The pellet was rehomogenized in Tris-BAME.
Membranes (50 Wg) were incubated in a ¢nal volume of 200 Wl with
[3H]AVP (5^50 nM) in Tris-BAME without or with unlabelled AVP
(5 WM) for 2 h at 25‡C at 300 rpm in a rotary water bath. The samples
were then transferred onto GF/C ¢lters (Whatman) pretreated with
0.1% polyethyleneimine and washed rapidly twice with PBS using a
Brandel cell harvester. Filters were ¢nally transferred into 5 ml vials,
and 4 ml of liquid scintillation cocktail was added. Radioactivity was
determined in a liquid scintillation counter.
2.6. Adenylyl cyclase assay
The preparation of nuclei-free crude membrane fractions from
CHO and HEK cells and the adenylyl cyclase assay were performed
as described [5].
2.7. Immuno£uorescence microscopy
COS.M6 cells grown on glass coverslips (12 mm) were washed twice
with PBS and ¢xed for 30 min with freshly prepared paraformalde-
hyde (2.5% (v/v)) in Na-cacodylate bu¡er (100 mM Na-cacodylate,
100 mM sucrose, pH 7.4). After two rinses with PBS, coverslips were
transferred either immediately or after permeabilization (0.1% Triton
X-100 in PBS for 3 min) into a humidifying chamber and incubated at
37‡C for 45 min with 20 Wl of the monoclonal c-myc antibody (9E10,
Dianova, Hamburg, Germany; 1:100 dilution in PBS). After three
rinses with PBS at room temperature cells were incubated at 37‡C
for 45 min in the humidifying chamber with 20 Wl of a polyclonal
cy3-conjugated rabbit anti-mouse IgG antibody (Dianova, Hamburg,
Germany; 1:400 dilution in PBS). After three ¢nal rinses cells were
mounted with a mixture of PBS/glycerol (1:1) containing 100 mg/ml
DABCO (1,4-diazobicyclo[2,2,2]octane, Sigma, Munich, Germany), to
reduce photobleaching. The samples were analyzed at Vexc = 525 and
Vems 568 nm with the LSM 410 invert laser scanning microscope
(Carl Zeiss, Jena, Germany). For microscopy of living cells,
COS.M6 or HEK cells expressing the V2R.EGFP or L336.EGFP
fusions were grown on 18U18 mm glass coverslips and incubated
for 15 min at 37‡C with rhodamine 6G (5 WM) or BODIPY TR
ceramide (5 WM) (both from Molecular Probes, Leiden, The Nether-
lands) for the staining of the ER or of the Golgi apparatus respec-
tively. The samples were analyzed with the LSM 410 at Vexc = 488 and
Vems 515 nm (EGFP), Vexc = 543 and Vems 570 nm (rhodamine 6G,
BODIPY TR ceramide).
3. Results
To elucidate the role of the intracellular C-terminus of the
V2 receptor in mediating cell surface expression and G protein
activation we used truncated receptors lacking 15^35 amino
acids (Fig. 1). The truncations are designated according to the
amino acid replaced by the nonsense codon and its position in
the V2 receptor. The shortest truncation mutant, R337X, has
been found in patients su¡ering from nephrogenic diabetes
insipidus [3] ; it encodes a V2 receptor mutant truncated
nine residues after the seventh transmembrane domain. Addi-
tional truncations investigated were L339X (includes the ¢rst
basic residue after the seventh transmembrane domain),
P349X (harbors three of four basic residues within the C-ter-
minus), D355X (additionally includes a proline-rich stretch),
and S357X (additionally includes two acidic residues). Full
length receptors in which basic residues in the C-terminus
were replaced by glutamines were also constructed.
Intact COS.M6 cells transiently expressing the naturally
occurring mutant R337X lacked any speci¢c binding using
10^50 nM [3H]AVP (see Table 1). Similar results were ob-
tained for the L339X mutant. In contrast, the receptors trun-
cated after residues 348, 354 and 356 displayed speci¢c bind-
ing and revealed KD (see Table 1) and EC50 values (Fig. 2A)
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Fig. 1. Primary sequence of the intracellular C-terminus of the V2
receptor. Posttranslational modi¢cations depicted are palmitoylation
at cysteine residues 341 and 342. Truncations investigated in this
study are marked with arrows. Basic residues of the C-terminus re-
placed by glutamines are marked as gray circles.
Table 1
Binding of [3H]AVP to intact COS.M6 cells expressing wild-type
and mutant V2 receptors
Bmax (% of wild-type) KD values (nM)
Wild-type (100) 2.8 þ 0.4
R337X n.d. ^
L339X n.d. ^
V2L2 n.d. ^
P349X 40 þ 10 2.6 þ 0.6
D355X 45 þ 12 2.1 þ 0.1
S357X 63 þ 9 2.7 þ 0.6
R337Q 52 þ 8 1.5 þ 0.5
K367Q 73 þ 5 2.9 þ 0.9
vposV2R 30 þ 7 3.0 þ 1.0
n.d.: not detectable.
Bmax and KD values of the wild-type and mutant V2 receptors are
shown. Data represent mean values þ S.D. from at least three inde-
pendent experiments.
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similar to those of the wild-type (EC50 values are given in the
legend to Fig. 2). However, the truncated receptors reveal
reduced Bmax values (see Table 1), which were lowest for
P349X and highest for S357X, indicating a relationship be-
tween the length of the C-terminus and the extent of cell sur-
face expression.
To detect receptors which are competent to bind [3H]AVP
but retained intracellularly, we prepared membranes of
COS.M6 and HEK cells transiently or of MDCK and CHO
cell clones stably expressing the R337X mutant. In contrast to
membranes from cells expressing the wild-type receptor, we
were unable to detect speci¢c binding of [3H]AVP (5^50 nM)
to membranes from those cells (Fig. 3). Experiments with the
L339X mutant yielded similar results (not shown). In agree-
ment with the binding data, adenylyl cyclase in membrane
preparations of HEK cells transiently or MDCK cells stably
expressing the R337X or the L339X mutant receptors did not
respond to AVP up to 1 WM (not shown).
To exclude the presence of normally transported receptors
with defective binding sites on the cell surface (R337X,
L339X), we performed immuno£uorescence on wild-type
and truncated V2 receptors carrying a c-myc epitope at the
extracellular N-terminus. In addition, the truncated receptors
with normal function (P349X, D355X) were analyzed. In non-
permeabilized COS.M6 cells (Fig. 4A) the wild-type receptor
and the mutants P349X and D355X were detected at the cell
surface, with the wild-type showing the most prominent sig-
nal. In contrast, the R337X mutant was not detected at the
cell surface. When cells were permeabilized (Fig. 4B) the mu-
tant R337X was easily detected, like the mutants P349X,
D355X or the wild-type V2 receptor. The relative intensities
of the £uorescent signals found for permeabilized cells ex-
pressing the wild-type or the truncated receptors were similar,
indicating that the tagged receptors are synthesized at com-
parable levels.
The immunoreactive signals of ¢xed COS.M6 cells express-
ing the various mutants did not allow the identi¢cation of
receptor-harboring compartments. We therefore expressed fu-
sion proteins consisting of the wild-type or truncated (after
L336) V2 receptor and the auto£uorescent green £uorescent
protein (EGFP, fused to the C-terminus of the V2 receptor).
This approach allowed the analysis of receptors within living
cells, and by visualizing organelles with speci¢c £uorescent
dyes, we were able to identify the subcellular distribution of
the fusion proteins. The wild-type receptor (V2R.EGFP) ex-
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Fig. 2. AVP dose response curves of membrane preparations. A:
Adenylyl cyclase activities in membrane preparations derived form
CHO cells stably expressing wild-type, P349X or D355X mutant V2
receptors. For each mutant two independently developed clones
were investigated. Data represent mean values of duplicates, which
di¡ered by less than 5%. EC50 values for the wild-type, the P349X
and the D355X mutants were 0.1 nM, 0.18 nM and 0.1 nM respec-
tively. B: Adenylyl cyclase activities in membrane preparations de-
rived from HEK cells transiently expressing the wild-type or the
vposV2R receptors. Data represent mean values of duplicates,
which di¡ered by less than 5%. EC50 values for the wild-type and
vposV2R mutants were 0.85 nM and 3 nM respectively. Basal, 250
nM AVP-stimulated, and 100 WM PGE1-stimulated adenylyl cyclase
activities were (in pmol cAMP/mg protein/min): 4.0, 20.3 and 15.1
for the wild-type and 4.0, 14.2 and 11.7 for the vposV2R mutant
respectively.
Fig. 3. [3H]AVP binding to membrane preparations of untransfected
cells (contr.) or of cells expressing the wild-type (WT), the R337X
mutant or the V2L2 chimeric receptors. Binding was performed with
5 nM [3H]AVP in the presence (white bar) or absence (black bar)
of 1 WM AVP. In case of CHO and MDCK cells stably transfected
clones were analyzed. The data represent mean values of duplicates,
which di¡ered by less than 5%. Similar results were obtained in at
least three independent experiments and in the case of stably trans-
fected cells from two independently derived cell clones.
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pressed in HEK and COS.M6 cells was located mainly at the
plasma membrane. Only in COS.M6 cells, which grossly over-
express, the receptor was also detected in a compartment near
the nucleus (Fig. 5), which colocalized with the Golgi marker
BODIPY TR ceramide (not shown). In contrast, the receptor
truncated after leucine 336 (L336.EGFP) was not detected at
the plasma membrane but exclusively found within the cell.
The signal obtained with the L336.EGFP fusion in HEK and
in COS.M6 cells colocalized with the £uorescent probe rhod-
amine 6G, which is enriched within the endoplasmic reticulum
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Fig. 5. Localization of wild-type and truncated V2 receptors fused
to EGFP protein in COS.M6 (A,C,D) and HEK cells (B,E,F). The
wild-type fusion protein (V2R.EGFP: A,B) was predominantly
found in the plasma membrane. In COS.M6 cells it was also de-
tected in the Golgi apparatus (A) as determined by colocalization
with BODIPY TR ceramide staining (not shown). The truncated re-
ceptor (L336.EGFP) was only detected within the cell (C,E) and co-
localized with rhodamine 6G staining (D,F) indicating its retention
within the endoplasmic reticulum. Note that rhodamine 6G also
stains untransfected COS.M6 cells. The analysis was performed with
a laser scanning microscope. Scale bar, 10 Wm.
Fig. 4. Immunolocalization of epitope-tagged wild-type or mutant
V2 receptors in COS cells. The wild-type or mutant receptors, with
an N-terminal c-myc epitope, were detected with a primary mono-
clonal anti-c-myc antibody and a secondary polyclonal cy3-conju-
gated antibody. A: Non-permeabilized cells ; B: permeabilized cells
(WT, R337X, P349X, D355X). Shown are focal planes of cells
(upper panels) and z-scans at the indicated lines (lower panels) ob-
tained by laser scanning microscopy. C: Non-permeabilized (V2L2
np) and permeabilized (V2L2 p) COS cells expressing the V2L2 chi-
meric receptor. Shown are focal planes of cells. Scale bar, 10 Wm.
6
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and in mitochondria [7] (see Fig. 5). Thus the mutant R337X
seems to be misfolded and is therefore retained within the ER.
To determine whether a speci¢c sequence in the C-terminus
is required for folding and cell surface expression, we con-
structed a chimera consisting of the amino-terminal part of
the V2 receptor including the seventh transmembrane domain
(amino acids 1^326 including the highly conserved NPXXY
motif) and the cytoplasmic C-terminus (downstream of the
NPXXY motif) of the L2-adrenergic receptor (amino acids
327^413). Transient expression of this chimera in COS.M6
cells or stable expression in CHO cells did not confer speci¢c
binding of [3H]AVP to intact cells or to membrane prepara-
tions (see Fig. 3 and Table 1). In addition, membrane prepa-
rations of CHO cells expressing the chimera showed no acti-
vation of adenylyl cyclase in response to vasopressin (up to 10
WM, not shown). Immuno£uorescence microscopy of the N-
terminally c-myc-tagged chimera revealed that this mutant is
retained within the cell, similarly to the R337X and the L339X
mutants (Fig. 4C). The results suggest that the proximal part
of the C-terminus harbors speci¢c residues required for a
transport-competent and functional receptor.
As basic residues are frequently found in the C-terminus of
GPCRs we analyzed the role of positively charged residues
within the C-terminus of the V2 receptor for cell surface ex-
pression. To this end we replaced arginine residues 337, 344,
346 and the lysine residue at position 367 by glutamine resi-
dues (vposV2R; see Fig. 1). Saturation binding to intact
COS.M6 cells expressing the vposV2R mutant revealed a low-
ered expression at the cell surface of about one third of that of
the wild-type (Table 1). Dose-response curves obtained with
membrane preparations from HEK cells transiently expressing
the mutant vposV2R stimulated adenylyl cyclase to the same
extent as the wild-type (Fig. 2B); the EC50 value was about 3-
fold higher than that of the wild-type receptor expressed in
HEK cells (EC50 values for WT and mutant receptors were
0.85 nM and 3 nM respectively). Single substitutions of argi-
nine 337 by glutamine (R337Q) and of lysine 367 by gluta-
mine (K367Q) reduced the level of cell surface expression to
about 50 and 75% of that of the wild-type respectively (see
Table 1). The KD values of the R337Q, K367Q and vposV2R
were similar to that of the wild-type receptor.
4. Discussion
The R337X mutation found in patients with nephrogenic
diabetes insipidus produces a full clinical phenotype [3], indi-
cating a substantial defect of the mutant V2 receptor. This is
of particular interest as the receptor, truncated within the
intracellular C-terminus nine amino acids after the seventh
transmembrane domain, should be correctly folded and be
functional. Sadeghi et al. [4] recently showed that the
R337X receptor is only core-glycosylated (endoglycosidase
H-sensitive), whereas the wild-type receptor is complex glyco-
sylated (endoglycosidase H-resistant). It was suggested that
the R337X mutant lacks signals required for exit from the
ER. We show here that the R337X mutant is misfolded (no
[3H]AVP binding in membrane preparations) and retained
within the ER. As positively charged residues are frequently
found in cytoplasmic sequences following hydrophobic stop/
transfer domains [8], it is possible that the absence of the
arginine 337, close to the seventh transmembrane domain,
causes misfolding. This is, however, opposed by the ¢nding
that the L339X mutant was also non-functional. Moreover,
the replacement of arginine 337 by glutamine in the full-length
receptor had no in£uence on functional activity.
Truncations of the C-termini of other GPCRs also resulted
in non-functional receptors. For example, truncation of the C-
terminus close (1^7 residues) to the seventh transmembrane
domain yielded non-functional receptors in case of the human
PTH receptor [9], the rat substance P receptor [10], the canine
histamine H2 receptor [11], the human endothelin A receptor
and the human neurokinin A receptor [12]. The removal of
the complete C-terminus of the TSH receptor caused a 100-
fold decrease of the KD and abolished Gs coupling [13]. For
bovine rhodopsin it was found that truncation of the receptor
one residue after the seventh transmembrane domain abol-
ished retinal binding; the mere presence of ¢ve additional
residues, but not their identity was essential for correct folding
[2]. Our ¢ndings suggest that speci¢c residues within the C-
terminus of the V2 receptor are required for correct folding
since the replacement of the C-terminus by that of the L2-
adrenergic receptor yielded a non-functional receptor. Inter-
estingly, a chimeric receptor protein consisting of the N-ter-
minal part of the human V2 receptor (amino acids 1^331) and
of the rat V1a receptor (amino acids 359^395) was found to
be functional with properties similar to that of the wild-type
V2 receptor [14]. The discrepancy of the e¡ects observed for
the chimeric receptor proteins, the V2L2 and the V2V1a chi-
meras, may be caused by the di¡erent fusion strategies. In the
V2V1a chimera the rat V1a C-terminus was fused to the hu-
man V2 receptor after serine 330, whereas in the V2L2 chi-
mera, the C-terminus of the human L2-adrenergic receptor
was fused after alanine 326. Alternatively, there may be a
requirement for speci¢c amino acids in the C-terminus for
proper folding. The amino acid sequence of the rat V1a re-
ceptor, although di¡erent from that of the human V2 recep-
tor, may harbor in some positions residues which allow cor-
rect folding, whereas the human L2-adrenergic receptor does
not possess these residues. The signi¢cance of cysteine resi-
dues 341 and 342 (shown to be palmitoylated in the wild-type
receptor [15]) for folding also has to be considered. Both
cysteine residues are lacking in the misfolded R337X and
L339X mutants. Replacement of both cysteine residues by
serines did not alter the V2 receptor’s functional properties
for [3H]AVP binding and AVP-induced stimulation of the
adenylyl cyclase [5]. We show here that the V2L2 chimera is
misfolded, despite the presence of a presumably palmitoylated
cysteine residue (cysteine 341 within the L2-adrenergic C-ter-
minus). Thus the palmitoylation of C-terminal cysteines is
apparently not required for proper folding.
The mechanisms underlying our ¢ndings remain specula-
tive. It is possible that speci¢c interactions (hydrogen bonds,
interactions of charged residues) between the residues of the
C-terminus and the three intracellular loops contribute to the
correct positioning of all seven helices. In fact, the solution
structure of a complex of the three intracellular loops and the
C-terminus of rhodopsin provided evidence for seven intra-
molecular bonds, ¢ve of them involving the N-terminal part
of the C-terminus [16]. Alternatively, the premature termina-
tion may disturb the correct positioning of transmembrane
domains in the ER membrane. Support for this hypothesis
comes from the ¢nding that peptides corresponding to the
¢rst and second intracellular loops of bovine rhodopsin pro-
duce well-ordered structures (in the absence of transmem-
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brane helices) [17]. It was suggested that folding of the loops
enables correct positioning of the transmembrane domains.
Whether ordered structures of the C-terminus of GPCRs are
also required for the correct positioning of the transmembrane
domain has not been investigated so far.
Besides the ¢nding that N-terminal residues of the V2 re-
ceptor are needed for proper folding, we show that the distal
C-terminus is required for e⁄cient transport to the cell sur-
face. While the truncations after residues 348, 354 and 356 did
not a¡ect ligand binding and G protein activation, they
caused substantially lowered expression of the receptor at
the cell surface. The length of the C-terminus of the rat
PTH receptor also in£uences cell surface expression. A dele-
tion of 78 or 111 residues decreased cell surface expression
and, in addition, decreased ligand a⁄nity 1.5- and 4-fold re-
spectively [18]. For rhodopsin it was shown that the C-termi-
nus harbours motifs important for transport. A monoclonal
antibody directed against the C-terminus inhibited vesicle for-
mation at the trans-Golgi network, resulting in accumulation
of completely processed receptors within this compartment
[19]. Not only the length of the C-terminus, but also the sub-
stitution of positively charged residues by glutamines within
the C-terminus of the V2 receptor caused reduction of cell
surface expression. Interestingly, of the 35 reported missense
mutations of the V2 receptor causing nephrogenic diabetes
insipidus, only two reside within the intracellular loops (spe-
ci¢cally the second intracellular loop, for review see [20]). The
mutations (R137H, R143P) are predictive for a replacement of
arginine in each case, either by histidine (which is usually not
protonated in the cytoplasmic environment) or proline; for
both, a reduced surface expression to 10% or less of the
wild-type was demonstrated [21,22]. As basic residues are fre-
quently found in the C-termini of many GPCRs it would be
of interest to determine whether removal of basic residues
a¡ect transport of other receptors in a similar way. It also
remains to be shown whether the reduced cell surface expres-
sion results from a hampered transport, e.g. from the ER or
Golgi to the plasma membrane or less likely misrouting, e.g.
to lysosomes.
Acknowledgements: We appreciate the excellent technical assistance of
Jenny Eichhorst and thank John Dickson for critical reading of the
manuscript. The work was supported by grants from the Deutsche
Forschungsgemeinschaft (SFB 249, SFB 366) and the Thyssen foun-
dation.
References
[1] Baldwin, J.M. (1993) EMBO J. 12, 1693^1703.
[2] Osawa, S. and Weiss, E.R. (1994) Mol. Endocrinol. 46, 1036^
1040.
[3] Bichet, D.G., Birnbaumer, M., Lonergan, M., Arthus, M.F.,
Rosenthal, W., Goodyer, P., Nivet, H., Benoit, S., Giampietro,
P., Simonetti, S., Fis, A., Whitley, C.B., Jaeger, P., Gertner, J.,
New, M., DiBona, F.J., Kaplan, B.S., Robertson, G.L., Hendy,
G.N., Fujiwara, T.M. and Morgan, K. (1994) Am. J. Hum.
Genet. 55, 278^286.
[4] Sadeghi, H.M., Innamorati, G. and Birnbaumer, M. (1997) Mol.
Endocrinol. 11, 706^713.
[5] Schuºlein, R., Liebenho¡, U., Muºller, H., Birnbaumer, M. and
Rosenthal, W. (1996) Biochem. J. 313, 611^616.
[6] Oksche, A., Schuºlein, R., Rutz, C., Liebenho¡, U., Dickson, J.,
Muºller, H., Birnbaumer, M. and Rosenthal, M. (1996) Mol.
Pharmacol. 50, 820^828.
[7] Terasaki, M. and Reese, T. (1992) J. Cell. Sci. 101, 315^322.
[8] Yamane, K., Akiyama, Y., Ito, K. and Mizushima, S. (1990)
J. Biol. Chem. 265, 21166^21171.
[9] Schneider, H., Feyen, J.H.M. and Seuwen, K. (1994) FEBS Lett.
351, 281^285.
[10] Sasakawa, N., Sharif, M. and Hanley, M.R. (1994) FEBS Lett.
347, 181^184.
[11] Fukushima, Y., Asano, T., Takata, K., Funaki, M., Ogihara, T.,
Anai, M., Tsukuda, K., Saitoh, T., Katagiri, H., Aihara, M.,
Matsuhashi, N., Oka, Y., Yazaki, Y. and Sugano, K. (1997)
J. Biol. Chem. 272, 19464^19470.
[12] Cyr, C.R., Rudy, B. and Kris, R.M. (1993) J. Biol. Chem. 268,
26071^26074.
[13] Chazenbalk, G.D., Nagayama, Y., Russo, D., Wadsworth, H.L.
and Rapoport, B. (1990) J. Biol. Chem. 265, 20970^20975.
[14] Liu, J. and Wess, J. (1996) J. Biol. Chem. 271, 8772^8778.
[15] Sadeghi, H.M., Innamorati, G., Dagarag, M. and Birnbaumer,
M. (1997) Mol. Pharmacol. 52, 21^29.
[16] Yeagle, P.L., Alderfer, J.L. and Albert, A.D. (1997) Biochemistry
36, 9649^9654.
[17] Yeagle, P.L., Alderfer, J.L., Salloum, A.C., Ali, L. and Albert,
A.D. (1997) Biochemistry 36, 3864^3869.
[18] Iida-Klein, A., Guo, J., Xie, L.Y., Juºppner, H., Potts, J.T., Kro-
nenberg, H.M., Brinhurts, F.R., Abou-Samra, A.B. and Segre,
G.V. (1995) J. Biol. Chem. 270, 8458^8465.
[19] Deretic, D., Puelo-Scheppke, B. and Trippe, C. (1996) J. Biol.
Chem. 271, 2279^2286.
[20] Oksche, A. and Rosenthal, W. (1998) J. Mol. Med. (in press).
[21] Rosenthal, W., Antaramian, A., Gilbert, S. and Birnbaumer, M.
(1993) J. Biol. Chem. 268, 13030^13033.
[22] Tsukaguchi, H., Matsubara, H., Taketani, S., Mori, Y., Seido, T.
and Inada, M. (1995) 96, 2043^2050.
FEBS 19907 5-3-98
A. Oksche et al./FEBS Letters 424 (1998) 57^6262
